Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales. The company also expects Amtagvi, Iovance’s treatment regimen for advanced melanoma, will have up to $1 billion in peak sales potential. Meanwhile, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) also provided an update on Lifileucel, an in-development treatment for lung cancer. The company said the commercial opportunity for Lifileucel could be up to 7x larger than the current opportunity in the melanoma treatment market. Lifileucel is expected to complete the enrollment and data updates process for the anti-lung cancer drug this year, with the drug anticipated to launch in the second half of 2027. The company also said it still has $307 million in cash & cash equivalents, which will fund its operations through the second quarter of 2027. Biopharmaceutical company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) develops and commercializes cell therapies as novel cancer immunotherapy products. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Most Undervalued Stocks to Buy and Hold for 5 Years Disclosure: None. This article is originally published at Insider Monkey.